|
|
Post by bernstein on Sept 21, 2016 13:21:26 GMT
This completely undiscovered low float is definitely one of the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Aequus has begun to Market 2 Drugs called Vistitan (Glaucoma) and Tacrolimus IR (Transplant) in first half 2016 in Canada and they got the Canadian rights for the Epilepsy drugs Trokendi XR and Oxtellar XR from Supernus Pharma (SUPN) earlier this year , NDS submission for Approval is expected in early 2017 .Peak sales for these 4 drugs is between $40-45 Million according to Management which is HUGE for this microcap stock with a ridiculous market cap of $10 Million .Management alone holding over 16 Million shares Ceo just bought 840k shares at 0.30 a few days ago .GLTA Aequus Pharma (AQS.V) (AQSZF) Market-Cap: $10 M Price: 0.21 Shares out: 54 Million Presentation August 2016 www.aequuspharma.ca/Investors/Aequus%20Pharmaceuticals%20August%202016.pdfMarketed Products : Tacrolimus IRAequus initiated promotional efforts for tacrolimus IR in December, 2015 • Tacrolimus products currently account for ~30% of a $300 million immunosuppressive market in Canada •Aequus is promoting the first to market generic version of Prograf (tacrolimus IR)Vistitan
•Aequus initiated commercial activities in Q2 2016 for Vistitan (bimatoprost 0.03%) • The Canadian glaucoma market in 2014 was estimated to be over $137 million, of which prostaglandins remain one of the primary treatment options.Topiramate XR (Epilepsy and Migraine) NDS submission to Health Canada in 1Q 2017 <<< Licensed from Supernus Pharma (SUPN) Oxcarbazepine XR (Epilepsy) NDS submission to Health Canada in 1Q 2017 <<< Licensed from Supernus Pharma (SUPN) NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License(If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301) AQS-1301, a transdermal aripiprazole product candidate in development for potential weekly use in the treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia and major depressive disorder. The currently available dosage forms of aripiprazole (sold primarily under the trade name Abilify®) reached total worldwide sales of over $8 billion USD in 2014. A once-weekly transdermal patch has the potential to improve medication adherence and reduce the frequency of relapse. Interview with Ceo Doug Janzen business.financialpost.com/midas-letter/podcast-aequus-pharmaceuticals-ceo-doug-janzen-on-the-low-cost-of-drug-commercialization-in-canadansaction in Canadian history. James West: Sure. Let me ask that another way: how do you plan to get to – I mean, how many of these deals can you do a year? Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales. James West: Sure. Have you built a pharmaceutical company before, Doug? Doug Janzen: I have. So I’ve been in this industry for 20 years. I was a banker, then I ran a therapeutic company called Cardiome Pharma; I built that from 50 million to over 1 billion at its peak, and exited after doing an $800 million license with Merck — still the largest license transaction in Canadian history.
 |
|
|
|
Post by bernstein on Sept 26, 2016 13:21:44 GMT
Great Management here / Massive undervalued ( Market cap c$18.3M) / New Deals regarding In and Outlicensing on the way . This undiscovered stock is a great buying opportunity with tremendous upside potential .GL
www.aequuspharma.ca/investors/press-release/aequus-provides-corporate-update-on-commercial-and-development-programs
Once-Weekly Transdermal Aripiprazole Patch Positive Proof of Concept Clinical Data for Once-Weekly Transdermal Aripiprazole Patch: Aequus’ once-weekly transdermal aripiprazole program is being developed for the treatment of certain psychiatric disorders. In the first half of 2016, Aequus announced positive results from an initial Proof of Concept clinical study, which suggested the current formulation may provide sustained, seven-day delivery of therapeutic doses of aripiprazole. Aequus is preparing for the follow-on, multi-dose bioavailability study expected to be initiated in the second half of 2016. Aequus has also expanded the patent portfolio for this program, with a patent issued / allowed in five major countries or regions, including the US, Russia, Mexico, Japan and Australia, and pending in multiple additional territories. Aequus owns worldwide rights to the formulation described in the issued patent, and will look to partner commercial rights in markets outside of Canada as the program continues to advance. Long-Acting Transdermal Anti-Nausea Patch Advancement of IP and Formulation Optimization for Long-Acting Transdermal Anti-Nausea Patch: Aequus is advancing a once-daily and up to a once-weekly transdermal doxylamine and pyridoxine combination patch for the treatment of nausea and vomiting in pregnancy (NVP). During the first half of 2016, the Company completed preclinical studies and expects to advance the current formulation into Proof of Concept clinical studies in the second half of 2016. Aequus has filed an international patent that covers the current formulation and has ownership of worldwide rights. Aequus has been engaging with third parties around partnering discussions for each of its internal programs, with a goal of ensuring the maximum benefit is realized by shareholders. --------------- Ian Ball – Former Global Head of Brand Maximization and Lifecycle Strategy with Novartis Strong relationships with key executives at Novartis and Sandoz Ability to structure low-upfront deals for valuable products
|
|
|
|
Post by bernstein on Sept 29, 2016 12:51:51 GMT
Good News Aequus Obtains Ontario Provincial Listing for Vistitan(TM) www.stockhouse.com/news/press-releases/2016/09/29/aequus-obtains-ontario-provincial-listing-for-vistitan"This is a major milestone since the launch of PrVistitan™ as Ontario accounts for over 40% of prescription volume in the prostaglandin class of medications," said Ian Ball, Chief Commercial Officer at Aequus. "Improved access to PrVistitan™ in Canada's largest market is expected to drive revenues towards during the remainder of 2016 and beyond." |
|
|
|
Post by bernstein on Jan 11, 2017 14:50:04 GMT
Im back on this unknown and super brutally underpriced Gem after a conversation with Ceo janzen .. Here is a reply from last friday
djanzen@aequuspharma.ca Jan 6 at 10:13 PM
Hello Bernstein and Happy New Year… Thanks for your email.
The share price has been a negative surprise over the last few months. The business is going well, sales are growing and we expect additional commercial deals for revenue generating products to be announced this quarter. We also are about to start the second clinical trial for our transdermal Abilify product this month and our partner Corium has begun work on the next two transdermal programs. We have a lot of confidence in the business model and expect big things in 2017. Tax loss selling hurt the share price in December but in general the share price has been weaker than I expected. I personally bought 1million shares in 2016 and plan to buy more once I come out of a trading blackout. Our goal is to be profitable before the end of 2017 which at that point will remove the requirement for going to investors for financings.
Happy to chat if you would like to have a phone call…
Best, Doug Janzen Chairman and CEO / CoFounder Aequus Pharmaceuticals
|
|
|
|
Post by bernstein on Jan 11, 2017 18:39:25 GMT
AQSZF is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $11 Million ,this stock must be the cheapest Biotech out there .Stock should be at minimum $2+ right now . www.aequuspharma.ca/Investors/AQS%20investor%20November%202016_web.pdfFile for CDN approval of Topiramate XR and Oxcarbazepine XR
Operational profitability estimated in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018 |
|
|
|
Post by bernstein on Feb 15, 2017 16:32:20 GMT
|
|
|
|
Post by bernstein on Mar 2, 2017 14:13:45 GMT
|
|
|
|
Post by bernstein on Mar 9, 2017 14:25:00 GMT
The bought deal financing creates a fantastic buying opportunity. There is a lot of big news on the way which will drive the sp much higher again like the AQS1301 topline results which are imminent(this month) and new Product acquisitions .The Stock is brutally undervalued with a laughable market cap of just US$15 million . fundamentals after financing : Marktcap: c$20.5 Million ( US$ 15.1 Million ) Cash: c$4.5 Million << enough untill mid 2018 Price 0.285 Aequus Successfully Completes Dosing in Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch... www.aequuspharma.ca/investors/press-release/aequus-successfully-completes-dosing-in-second-proof-of-concept-clinical-trial-of-transdermal-aripipThe Company expects to report topline results from this multi-dose study in the first quarter of 2017. |
|
|
|
Post by bernstein on Mar 13, 2017 14:17:06 GMT
Financing is closed today and Aequus got the full amount of cash which is good News . Aequus Raises $5.2 Million Through Bought Deal Financing Including Full Exercise of the Over-Allotment Option www.marketwired.com/press-release/aequus-raises-52-million-through-bought-deal-financing-including-full-exercise-over-tsx-venture-aqs-2202413.htmThe Company has now cash untill mid 2018 excluding Product Sales and new Partner Deals . A lot of big news are on the way which could push the stock much higher . Management and Institutions alone holding almost 70% of Company Shares . AQS is a must have at these ridiculous low price. This one has the potential to run like Biosyent (RX.V) which went from 0.10 to over $10 now at $7.50 . Market-Cap: c$20.5 Million (US$15.15 Million) Cash: c$5.1 Million << enough untill mid 2018 Price: $0.22 Presentation www.aequuspharma.ca/Investors/AQS%20investor%20November%202016_web.pdfAQS1301 topline results in 1Q 2017 Operational profitability estimated in 2017 File for CDN approval of Topiramate XR in 1H 2017 File for CDN approval of Oxcarbazepine XR in 1H 2017 Additional Product acquisitions in 2017 Partnership for AQS1301 in 2017 Two products launches to date (Tacrolimus IR and Vistitan™) 3 long-acting, transdermal programs in development, on track to file NDA in 2018 MUST Watch www.youtube.com/watch?v=jV00WmYBtv4Podcast: Aequus Pharmaceuticals CEO Doug Janzen on the low cost of drug commercialization in Canada business.financialpost.com/midas-letter/podcast-aequus-pharmaceuticals-ceo-doug-janzen-on-the-low-cost-of-drug-commercialization-in-canadaJames West: Sure. Have you built a pharmaceutical company before, Doug? Doug Janzen: I have. So I’ve been in this industry for 20 years. I was a banker, then I ran a therapeutic company called Cardiome Pharma; I built that from 50 million to over 1 billion at its peak, and exited after doing an $800 million license with Merck — still the largest license transaction in Canadian history. James West: Sure. Let me ask that another way: how do you plan to get to – I mean, how many of these deals can you do a year? Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales. |
|
|
|
Post by hansgruber on Mar 13, 2017 15:15:15 GMT
just tried to dabble in this stock and etrade won't let me execute this online. Any ideas why bernstein?
|
|
|
|
Post by JHam on Mar 30, 2017 8:41:20 GMT
just tried to dabble in this stock and etrade won't let me execute this online. Any ideas why bernstein? This one got buried down deep so if you don't quote him, then he may not realize you asked the question. |
|
|
|
Post by JHam on Mar 30, 2017 8:41:42 GMT
Financing is closed today and Aequus got the full amount of cash which is good News . Aequus Raises $5.2 Million Through Bought Deal Financing Including Full Exercise of the Over-Allotment Option www.marketwired.com/press-release/aequus-raises-52-million-through-bought-deal-financing-including-full-exercise-over-tsx-venture-aqs-2202413.htmThe Company has now cash untill mid 2018 excluding Product Sales and new Partner Deals . A lot of big news are on the way which could push the stock much higher . Management and Institutions alone holding almost 70% of Company Shares . AQS is a must have at these ridiculous low price. This one has the potential to run like Biosyent (RX.V) which went from 0.10 to over $10 now at $7.50 . Market-Cap: c$20.5 Million (US$15.15 Million) Cash: c$5.1 Million << enough untill mid 2018 Price: $0.22 Presentation www.aequuspharma.ca/Investors/AQS%20investor%20November%202016_web.pdfAQS1301 topline results in 1Q 2017 Operational profitability estimated in 2017 File for CDN approval of Topiramate XR in 1H 2017 File for CDN approval of Oxcarbazepine XR in 1H 2017 Additional Product acquisitions in 2017 Partnership for AQS1301 in 2017 Two products launches to date (Tacrolimus IR and Vistitan™) 3 long-acting, transdermal programs in development, on track to file NDA in 2018 MUST Watch www.youtube.com/watch?v=jV00WmYBtv4Podcast: Aequus Pharmaceuticals CEO Doug Janzen on the low cost of drug commercialization in Canada business.financialpost.com/midas-letter/podcast-aequus-pharmaceuticals-ceo-doug-janzen-on-the-low-cost-of-drug-commercialization-in-canadaJames West: Sure. Have you built a pharmaceutical company before, Doug? Doug Janzen: I have. So I’ve been in this industry for 20 years. I was a banker, then I ran a therapeutic company called Cardiome Pharma; I built that from 50 million to over 1 billion at its peak, and exited after doing an $800 million license with Merck — still the largest license transaction in Canadian history. James West: Sure. Let me ask that another way: how do you plan to get to – I mean, how many of these deals can you do a year? Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales. hans has a question for you above. |
|
|
|
Post by bernstein on Apr 3, 2017 13:04:09 GMT
|
|
|
|
Post by bernstein on Apr 6, 2017 15:42:38 GMT
Up she goes again and still heavily undervalued ... Another product acquisition imminent , im very optimistic that this unknown stock will hit $1 before year end . Must Watch to realize the mega potential here www.youtube.com/watch?v=jV00WmYBtv4 |
|
|
|
Post by bernstein on Apr 10, 2017 13:30:54 GMT
AQS is very close to acquire rights up to 9 Marketed Products with these Products aequus will have 11 Marketed Products so you can be sure that they will reach profitability very quickly . Now add Aequus other real Big drugs Oxcarbazepine XR ,Topiramate XR and AQS1301 which all three Drugs are expected to enter the Market by around mid 2018 with these Drugs revenue will explode to the upside i think peak sales for all the products mentioned above can hit $100 MILLION in revenue .This goldmine with a dirt low market cap of US$15 million has really tremendous upside potential . 9 Products + Vististan + Tacrolimus = Peak Sales of $15 Million Topiramate XR +Oxcarbazepine XR = Peak Sales of $40 Million AQS1301 (AQS has global rights) = Peak Sales of minimum $50 million (USA alone)  Ceo Janzen is talking about these 4 drugs Topiramate XR Oxcarbazepine XR ,Vististan & Tacrolimus in the interview below business.financialpost.com/midas-letter/podcast-aequus-pharmaceuticals-ceo-doug-janzen-on-the-low-cost-of-drug-commercialization-in-canadaDoug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales. AQS1301 NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License (If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301) The Abilify brand and generic tablets had U.S. sales of approximately $3.1 billion MAT for the most recent twelve months ending in August 2016 according to IMS Health*. |
|
|
|
Post by bernstein on May 8, 2017 17:09:28 GMT
ceo bought another 95000 shares now holding over 4.7 million shares . this undiscovered stock is terrible undervalued with a market cap of $12 million . This stock should be at $2 instead of 25 pennies . www.canadianinsider.com/company?menu_tickersearch=aqsMay 5/17 May 5/17 Janzen, Doug Direct Ownership Common Shares 10 - Acquisition in the public market 50,000 $0.250 May 5/17 May 3/17 Janzen, Doug Direct Ownership Common Shares 10 - Acquisition in the public market 45,500 $0.230 >>>>>>NEW interview with Ceo // May, 2017<<<<<< biotech-tv.com/c/mid,1770,OnDemand/?v=297513 |
|
